• Deutsch
  • Home
  • Search
  • Browse
  • Publish
  • Help
Schließen

Refine

Has Fulltext

  • yes (1)

Is part of the Bibliography

  • yes (1)

Year of publication

  • 2020 (1)

Document Type

  • Journal article (1)

Language

  • English (1)

Keywords

  • NGS (1)
  • POU6F2-AS2 (1)
  • cancer (1)
  • cfRNA (1)
  • ddPCR (1)
  • early detection (1)
  • liquid biopsy (1)

Author

  • Aigner, Clemens (1)
  • Bielefeld, Nicola (1)
  • Cima, Igor (1)
  • Forster, Jan (1)
  • Hegedüs, Balazs (1)
  • Horn, Peter A. (1)
  • Klein, Christoph A. (1)
  • Kunzmann, Volker (1)
  • Lueong, Smiths S. (1)
  • Metzenmacher, Martin (1)
+ more

Institute

  • Medizinische Klinik und Poliklinik II (1)

EU-Project number / Contract (GA) number

  • 641458 (1)

1 search hit

  • 1 to 1
  • BibTeX
  • CSV
  • RIS
  • XML
  • 10
  • 20
  • 50
  • 100
Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer (2020)
Metzenmacher, Martin ; Váraljai, Renáta ; Hegedüs, Balazs ; Cima, Igor ; Forster, Jan ; Schramm, Alexander ; Scheffler, Björn ; Horn, Peter A. ; Klein, Christoph A. ; Szarvas, Tibor ; Reis, Hennig ; Bielefeld, Nicola ; Roesch, Alexander ; Aigner, Clemens ; Kunzmann, Volker ; Wiesweg, Marcel ; Siveke, Jens T. ; Schuler, Martin ; Lueong, Smiths S.
Early detection of cancer holds high promise for reducing cancer-related mortality. Detection of circulating tumor-specific nucleic acids holds promise, but sensitivity and specificity issues remain with current technology. We studied cell-free RNA (cfRNA) in patients with non-small cell lung cancer (NSCLC; n = 56 stage IV, n = 39 stages I-III), pancreatic cancer (PDAC, n = 20 stage III), malignant melanoma (MM, n = 12 stage III-IV), urothelial bladder cancer (UBC, n = 22 stage II and IV), and 65 healthy controls by means of next generation sequencing (NGS) and real-time droplet digital PCR (RT-ddPCR). We identified 192 overlapping upregulated transcripts in NSCLC and PDAC by NGS, more than 90% of which were noncoding. Previously reported transcripts (e.g., HOTAIRM1) were identified. Plasma cfRNA transcript levels of POU6F2-AS2 discriminated NSCLC from healthy donors (AUC = 0.82 and 0.76 for stages IV and I–III, respectively) and significantly associated (p = 0.017) with the established tumor marker Cyfra 21-1. cfRNA yield and POU6F2-AS transcript abundance discriminated PDAC patients from healthy donors (AUC = 1.0). POU6F2-AS2 transcript was significantly higher in MM (p = 0.044). In summary, our findings support further validation of cfRNA detection by RT-ddPCR as a biomarker for early detection of solid cancers.
  • 1 to 1

DINI-Zertifikat     OPUS4 Logo

  • Contact
  • |
  • Imprint
  • |
  • Sitemap